After A Dry 2013, Daiichi Sankyo Looks To Partners To Make It Rain
This article was originally published in PharmAsia News
Executive Summary
With only one deal in the last year, Daiichi Sankyo is ready for more deal-making with a new biz dev head and the acquisitions of oncology company Plexxikon and generics play Ranbaxy well behind it.